Committees : Surrey Heartlands Medicines Optimisation Board (MOB)

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

The Medicines Optimisation Board approved the updated primary care guidance for multi-professional prescribers.

Note: Multi-professional prescribing (MPP) was formerly referred to as “non-medical prescribing” and known as independent prescribing; however, this newer term reflects a wider number of healthcare professionals who can prescribe within their scope of practice once they have completed an approved education programme and is more accurate and inclusive. This term is increasingly being adopted by professional bodies including the Royal Pharmaceutical Society (RPS) who author the prescribing competency framework.

After undertaking a review of previous decisions and resources relating to transgender health, the APC agreed an AMBER status for oestrogen, testosterone, cyproterone, finasteride, GnRH & medroxyprogeterone when used in adults. 

Primary care initiation of these drugs is supported by the APC if the prescriber is competent to exercise their share of clinical responsibility and is assured that the shared care protocol provides enough information for them to discharge their responsibilities safely.

A guide to support primary care prescribing for people who access gender identity services was also agreed by the APC. 

The guide includes information on children and young people, requests to prescribe, shared care, on-going care and private providers.

The Surrey Heartlands Medicines Optimisation Board have approved the updated policy to support primary care, NHS prescribers when receiving requests to prescribe for their patients following private referral or episodes of private care.

The policy includes a number of resources to support communication with specialists and patients and to aid informed decision making.

Please refer to the policy for information

Admission to Hospital check-list (see document below)

This document can be used as a guide to assist care home staff to ensure all necessary information, medication and personal items are sent with a care home resident, when they are admitted to hospital.

It should be used in conjunction with other guidance or policies or specific requests from the admitting hospital. This list is not exhaustive and there may be other documents/items which should accompany the resident.

Hypertension / Blood Pressure Checks in Community Pharmacy.

Community Pharmacy Surrey & Sussex have produced a summary of the key features and differences between the BP+ (the locally commissioned service) and the Hypertensive Case Finding Service (Advanced National Service).

The summary of the two services can be found below

DO NOT prescribe in primary care.

This drug is recommended in the treatment of COVID-19 ONLY in line with NHSE commissioning policies which include detail on eligibility and exclusion criteria for:

• Non-hospitalised patients - Refer eligible patients from Surrey Heartlands and Frimley to the East Berkshire Primary Care Covid Medicine Delivery Unit.
• Hospitalised patients – Hospital treatment of those with acute Covid-19 illness OR with hospital onset Covid-19